PROSHADE Protocol: Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study
Por:
Lumbreras, B, Parker, LA, Alonso-Coello, P, Mira-Bernabeu, J, Gomez-Perez, L, Caballero-Romeu, JP, Pertusa-Martinez, S, Cebrian-Cuenca, A, Moral-Pelaez, I, Lopez-Garrigos, M, Canelo-Aybar, C, Ronda, E, Guilabert, M, Prieto-Gonzalez, A, Hernandez-Aguado, I
Publicada:
1 ago 2022
Resumen:
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients' perspective in their design. We aim to systematically develop and test a patient decision aid to promote SDM in prostate cancer screening, following the Knowledge to Action framework. Methods: (1) Feasibility study: a quantitative survey evaluating the population and clinician (urologists and general practitioners) knowledge of the benefits and risks derived from PSA determination and the awareness of the available recommendations. Focus groups to explore the challenges patients and clinicians face when discussing prostate cancer screening, the relevance of a decision aid and how best to integrate it into practice. (2) Patient decision aid development: Based on this data, an evidence-based multicomponent SDM patient decision aid will be developed. (3) User-testing: an assessment of the prototype of the initial patient decision aid through a user-testing design based on mix-methods (questionnaire and semi-structured review). The decision aid will be refined through several iterative cycles of feedback and redesign. (4) Validation: an evaluation of the patient decision aid through a cluster-randomised controlled trial. Discussion: The designed patient decision aid will provide balanced information on screening benefits and risks and should help patients to consider their personal preferences and to take a more active role in decision making. Conclusions: The well-designed patient decision aid (PDA) will provide balanced information on screening benefits and risks and help patients consider their personal preferences.
Filiaciones:
Lumbreras, B:
Miguel Hernandez Univ, Dept Publ Hlth Hist Sci & Gynecol, Alacant 03550, Spain
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Parker, LA:
Miguel Hernandez Univ, Dept Publ Hlth Hist Sci & Gynecol, Alacant 03550, Spain
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Alonso-Coello, P:
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Biomed Res Inst St Pau, Iberoamer Cochrane Ctr, Dept Clin Epidemiol & Publ Hlth, Barcelona 08001, Spain
Mira-Bernabeu, J:
Hosp Univ San Juan, Dept Prevent Med, Alacant 03550, Spain
Gomez-Perez, L:
Hosp Univ San Juan, Dept Urol, Alacant 03550, Spain
Caballero-Romeu, JP:
Hosp Gen Univ Alicante, Dept Urol, Alicante 03010, Spain
Pertusa-Martinez, S:
Cabo Huertas Healthcare Ctr, Alicante 03540, Spain
Cebrian-Cuenca, A:
Cartagena Casco Healthcare Ctr, Cartagena 30201, Spain
Moral-Pelaez, I:
Inst Invest Biomed St Pau, Unidad Invest, Equipo Atenc Primaria Sardenya, Barcelona 08001, Spain
Lopez-Garrigos, M:
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Hosp Univ San Juan, Clin Lab, Alacant 03550, Spain
Canelo-Aybar, C:
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Biomed Res Inst St Pau, Iberoamer Cochrane Ctr, Dept Clin Epidemiol & Publ Hlth, Barcelona 08001, Spain
Ronda, E:
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
Alicante Univ, Publ Hlth Res Grp, San Vicente Del Raspeig 03690, Spain
Guilabert, M:
Miguel Hernandez Univ, Dept Hlth Psychol, Elche 03202, Spain
Prieto-Gonzalez, A:
Canc Prostate Assoc ANCAP, Murcia 30012, Spain
Hernandez-Aguado, I:
Miguel Hernandez Univ, Dept Publ Hlth Hist Sci & Gynecol, Alacant 03550, Spain
CIBERESP, CIBER Epidemiol & Publ Hlth, Madrid 28029, Spain
gold, Green Published
|